RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing Re...
What is the expected impact on the stock volatility and options implied volatility following this release?
How does the company's valuation (e.g., P/E, EV/Revenue) compare to peers in the oncology device space?
What potential risks could arise from the Phase III trial, such as safety concerns or delayed enrollment?
27 days ago